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The delivery of electric pulses has been widely used to transfect cells in vitro (1, 2) . The extension of this procedure to "in vivo" systems is recent, and has been applied to many tissues such as skin (3), artery (4) liver (5, 6), tumor (7, 8) , muscle (9-13) cornea (14), brain (15) and spleen (16) . Many procedures have used unipolar square wave electric pulses with imposed voltages of short duration and high electric field intensity (5, 12) or of long duration (more than 5 ms) and lower intensity (6, 7, 11, 17) . Bipolar pulses have been also used (11). More recently, square wave monopolar electric pulses with imposed intensity of current have been developed (13).
Skeletal muscle is the most widely targeted tissue for plasmid electrotransfer, because it offers several advantages. It is easily accessible and is able to produce secreted proteins (18). Muscle fibers have a long lifespan, which allows a longterm (more than a year) expression in transfected cells (10).
Local expression of some proteins as amplified by electrotransfer can be useful for treatment of myopathies. Thus the expression of laminin α2 chain in dystrophic mouse muscles was obtained without extended muscle damage (19) . Such a result is encouraging because it shows that electrotransfer is presently possible on fragile muscle, even if some improvements are necessary.
The possibility to use muscle for secretion of therapeutic proteins into circulation opens a large field of applications. Electrotransfered muscle can efficiently produce and secrete growth or clotting factors (20, 21) . For instance, a therapeutic level of factor IX was detected for several weeks in mice (18). Two groups have recently shown that erythropoietin (Epo) secretion after muscle electrotransfer results in improved erythropoiesis, improvement in red cells half-life and phenotype, and high hematocrit value for several months in a β-thalassemic mouse model (21, 22) . This could be developed as a treatment for βthalassemia, or anemia as shown by Maruyama et al. (23) . Chronic renal failure is also a promising target for Epo-electrotransfer therapy. However progress in this field might require an inducible system for the temporal control of gene expression. Such a system is not yet available for human use.
Also by intramuscular electrotransfer, HGF secretion recently showed cytoprotective activity in mice with acute liver injury (24). Another promising result was recently obtained by Prud'homme et al. (25) , who showed protection against autoimmune diabetes by muscle secretion of a ligand of CTLA-4 (cytotoxic T lymphocyte antigen 4), which is a negative regulator of T cell activity.
Skeletal muscle has also been used for cytokine production that resulted in improved survival in a mouse viral myocarditis model (26) and in rat induced myocarditis (27). Antiinflammatory cytokine IL-10 showed interesting properties in an atherosclerosis model by limiting plaque formation at the aortic cross following an atherogenic diet (28). However this work showed that IL-10 electrotransfer could protect IL-10 knock out mice. More clinically relevant IL-10 plasmid electrotransfer was demonstrated to display a protective property in mouse model of collagen induced polyarthrite (29).
However to deliver high and sustained cytokine level in the circulation could induce non-physiological effects, since these molecules are devoted to exert local effects. Circulating cytokines might interact with non-desired tissues. The recent finding that spleen lymphocytes can be electrotransfered in situ is an interesting approach (16). Some transfected lymphocytes were found in other locations few days after spleen electrotransfer. Thus, one can imagine a biological targeting of inflammation sites via the homing at inflammatory sites of lymphocytes pretransfected in the spleen.
Among the different diseases that could potentially be treated by gene therapy, special attention has been devoted to cancer. In this field, different strategies can be used, among which suicides genes, immune stimulating cytokines, antiangiogenesis or tumor suppressors factors (30, 31) . Some of these strategies have been recently applied by in vivo electrotransfer in tumor tissues, with encouraging results, showing the feasibility of this approach. For example, suicide gene therapy using HSVtk/ganciclovir technology reduced the growth and metastasis of subcutaneously grafted mammary tumors in mice (32). Electroporation of cytokines into tumors has been also used: IFN-α (33), IL-12 or 35) has recently been shown to reduce tumor growth and increase survival times in different tumor models. Significant inhibition of tumors growth was also obtained by intratumoral electroporation of TRAIL/Apo2 ligand, an apoptosis inducer (36), We have shown that electrotransfer of the antisense of Mdb2b, an enzyme involved in DNA methylation, into a human tumor model (H1299) grafted in nude mice, slows tumor growth (37).
As the number of transfected cells is probably not sufficient, electrotransfer of tumor mass tissue might not lead by itself to a cure of cancer. Nevertheless several papers show cure of cancer after plasmid electrotransfer to tumor, along with resistance to challenge with tumor cells. Distal antitumor effects have also been observed after intratumor electrotransfer (38) (39) (40) (41) . Furthermore, the efficiency of gene transfer depends on the tumor tissue (8). However, electrotransfer should be used in combination with other strategies such as chemotherapy. As chemotherapy and gene therapy follow different mechanisms to kill cancer cells, a synergy between them can reasonably be expected, in addition to a different toxicity profile. Such an approach was tested in the work of Heller, L. et al. (42) . Also, distal treatment of the tumor by using electrotransfered muscle to secrete anticancer molecules can be useful. Such a strategy was tested with metalloproteinase-4 inhibitor (43). Also, Li, S. et al. (44) showed that muscle electrotransfer with a plasmid coding for IFNalpha increased survival time and reduced squamous cell carcinoma (SCC) growth, at a distant site from the muscle in C3H/HeJ-immunocompetent mouse. And one can imagine the combination of distal and local treatments.
In addition to its potential use in gene therapy, in vivo DNA transfer by electroporation is also, because of its simplicity, a powerful laboratory tool to study in vivo gene expression in a given tissue. As already stated, efficient conditions for plasmid electrotransfer have been described in several tissues. As an example, in vitro and in vivo electroporation, along with modelisation by bioinformatic analysis, have been used to decipher the transcriptional regulation of human skeletal muscle myosin heavy chain in muscle development and differentiation (45). In vivo electroporation has also proved to be a valuable tool for the study of gene regulation systems, such as the tetracycline system, which requires at least cotransfection of two plasmids in the same cell (46). For instance, Lamartina et al. studied the activity of novel doxycycline transactivators in a gene switch system (47), and we studied a system based on hypoxia-responsive element and tetracycline transactivators (48).
As future potential applications, one can note that electrotransfer enhances the level of blood antibodies and cytotoxic immune responses (49, 50) raising perspectives in the vaccination fields. Also the veterinary use of electrotransfer could be the first application to be developed for instance to increase growth or prevent cachexy using stimulation of growth hormone (51).
In conclusion, plasmid electrotransfer has emerged as an easy and efficient method for transfection of different tissues. This can be used for both local action or for distal effect by secretion of the transgenic proteins in the circulation. Many therapeutic strategies can thus be easily tested on animal models. As it does not induce the immune system, electrotransfer of a self protein can be repeated as often as desired. Independently, this user-friendly, simple technology could become a versatile tool for post-genome functional studies and for gene validation in general. To warrant physiological conditions in experimental models and if clinical applications are envisioned, it will be necessary to further investigate the possible toxic effects of electrotransfer and how to prevent them. To develop inducible expression systems for human use is also necessary. However we have seen that it is already possible to collect data relevant to therapeutic and for postgenome application with the electrotransfer technique.
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